rs3856806 — PPARG His477His (C1431T)

Synonymous PPARG variant where the T allele reduces type 2 diabetes risk and improves LDL and HDL cholesterol despite no amino acid change

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG C1431T — The Silent Variant That Speaks Volumes

PPARG (peroxisome proliferator-activated receptor gamma) is the master regulator of adipogenesis11 Adipogenesis: the differentiation of precursor cells into mature fat-storing adipocytes. PPARG is required for this process — without it, adipocytes cannot form. and a central hub for insulin sensitivity. It is the molecular target of thiazolidinedione drugs22 Thiazolidinediones such as pioglitazone and rosiglitazone directly activate PPARG to improve insulin sensitivity in type 2 diabetes — making PPARG variants especially relevant for predicting drug response. used to treat type 2 diabetes. The rs3856806 variant (C1431T, His477His) sits in exon 6 of PPARG and does not change the histidine amino acid at position 477 — but it does affect how the gene is expressed, making it one of the most studied PPARG variants in metabolic disease genetics.

The Mechanism

Although His477His produces no amino acid change, the C-to-T substitution is not biologically neutral. The T allele is thought to alter mRNA 33 mRNA processing: synonymous variants can shift splicing efficiency, change mRNA stability, or alter the rate of codon translation, all without changing the protein sequence. processing in a way that modestly increases adipocyte differentiation capacity. More differentiated adipocytes tend to be smaller and more insulin-sensitive, which may explain the T allele's associations with improved glucose metabolism and lipid profiles. The C1431T variant shows stronger linkage disequilibrium with the PPARG haplotype block associated with metabolic outcomes than the Pro12Ala (rs1801282) variant in the same gene, and in some populations it is a better predictor of fasting insulin levels and insulin resistance than Pro12Ala alone.

The Evidence

A meta-analysis of 9 studies44 meta-analysis of 9 studies
Tiongco et al. Association of the rs3856806 Polymorphism in the PPARG Gene with T2DM: A Meta-Analysis of 11,811 Individuals. Lab Med, 2023 encompassing 11,811 individuals found that carrying the T allele significantly reduces type 2 diabetes risk (allelic model OR 0.82; 95% CI 0.76–0.89; P < .00001), with consistent results across co-dominant, dominant, and recessive models.

A separate meta-analysis of 33 studies55 meta-analysis of 33 studies
Li et al. G Allele of rs1801282 Confers Increased Risk of Obesity; T Allele of rs3856806 Displays Protective Role Against Dyslipidemia. Front Endocrinol, 2022 covering 18,353 subjects found that T allele carriers had meaningfully lower LDL-cholesterol (SMD −0.09 mmol/L; 95% CI −0.15 to −0.03; p < 0.01) and higher HDL-cholesterol (SMD +0.06 mmol/L; 95% CI 0.02 to 0.10; p < 0.01) compared to CC homozygotes. Importantly, this meta-analysis found no significant association between rs3856806 and BMI when examined in isolation.

A haplotype study66 haplotype study
Valve et al. Haplotype analysis of PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet, 2002 in over 1,700 individuals (including 1,107 type 2 diabetics) clarified an important nuance: when C1431T and Pro12Ala are analyzed together as haplotypes, they have opposing effects on body weight. The common Pro-C haplotype is the neutral baseline. The Ala-C haplotype (Ala12 + C1431) is weight-protective, while the Pro-T haplotype (Pro12 + T1431) carries an increased BMI (β = +2.9 kg/m²; p = 0.002). This explains why studies examining C1431T alone find inconsistent BMI results — the T allele co-segregates with Pro12 in ~70% of carriers.

A Japanese cohort study77 Japanese cohort study
Nakashima et al. PPARγ2 C1431T genotype increases metabolic syndrome risk in young men with low cardiorespiratory fitness. Physiol Genomics, 2011 in 716 adults found that CC genotype combined with low cardiorespiratory fitness significantly increased metabolic syndrome risk in men under 40, while higher fitness levels attenuated the genetic difference between CC and T-allele carriers.

Practical Implications

The T allele (present in approximately 22% of Europeans as CT heterozygotes and 2% as TT homozygotes) is associated with a more favorable metabolic profile — lower LDL-C, higher HDL-C, and reduced T2D risk. For CC homozygotes (~76% of people of European descent), cardiorespiratory fitness is especially actionable: low fitness amplifies the absence of the T allele's protective effects, particularly in younger men. Monitoring lipid and glucose trends is useful for CC carriers to detect early metabolic drift that T allele carriers are less susceptible to.

Interactions

The key interaction for this variant is with rs1801282 (Pro12Ala) in the same PPARG gene. These two variants form haplotypes with opposing effects: the Ala-C haplotype (rs1801282 G + rs3856806 C) is weight-protective, while the Pro-T haplotype (rs1801282 C + rs3856806 T) modestly increases BMI despite the T allele's metabolic benefits. CC carriers of rs3856806 on the Pro12 background represent the population-typical neutral haplotype. The rs17036314 variant (PPARG intron 2) compounds with physical activity to further modify T2D risk in individuals with impaired glucose tolerance.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard PPARG Activity Normal

Common variant — population-typical metabolic profile

The CC genotype is the reference state for PPARG exon 6. A 2011 Japanese cohort study (PMID 21156835) found that CC genotype men under 40 with low cardiorespiratory fitness had significantly higher metabolic syndrome rates than CT/TT carriers or high-fitness individuals — suggesting that aerobic conditioning is especially important for CC homozygotes. The CC genotype is also the more common background for the Pro12 PPARG haplotype (Pro-C), the metabolically neutral baseline in haplotype studies. Two large meta-analyses found that the T allele (absent in CC carriers) consistently lowers LDL-C by ~0.09 mmol/L and raises HDL-C by ~0.06 mmol/L — the CC genotype lacks these advantages but is not itself a risk allele.

CT One Protective T Allele Beneficial

One T allele — lower T2D risk and improved lipid profile

The CT genotype confers partial benefit from the T allele's effect on PPARG mRNA processing. A 2022 meta-analysis (33 studies, 18,353 subjects, PMID 35846293) found that T carriers had LDL-C approximately 0.09 mmol/L lower and HDL-C approximately 0.06 mmol/L higher than CC homozygotes — modest but consistently replicated differences. A meta-analysis of 9 studies (11,811 individuals, PMID 36214523) confirmed 18% reduced odds of developing type 2 diabetes per T allele (OR 0.82). The haplotype context matters: ~70% of T allele carriers carry it on a Pro12 background (Pro-T haplotype), which is associated with a slight BMI increase that partially offsets the metabolic lipid and glucose advantages.

TT Two Protective T Alleles Beneficial

Two T alleles — strongest PPARG-mediated protection against T2D and dyslipidemia

TT homozygotes carry two copies of the T allele, fully expressing the altered PPARG mRNA processing associated with this variant. The T2D risk reduction is estimated at approximately 18% per allele in allelic models (OR 0.82 per copy, PMID 36214523). The lipid advantages (lower LDL-C, higher HDL-C) confirmed in the 33-study meta-analysis (PMID 35846293) are expected to be maximal in TT homozygotes, though TT-specific stratum data are limited given the low genotype frequency (~2% in Europeans). The Pro-T haplotype effect on BMI (β = +2.9 kg/m², PMID 12429071) applies to TT carriers who also carry Pro12 at rs1801282, which applies to the majority of T allele carriers.